文献速递妇科

调控代谢反应可在宫颈癌细胞系和异种移植瘤中增强SHetA2疗效且无毒性

Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts.
PubMed 文献 · Gynecol Oncol · 2023-12-05

研究在HPV阳性与阴性宫颈癌细胞系及SiHa异种移植瘤中观察SHetA2的代谢作用,发现SHetA2抑制氧化磷酸化后细胞代偿性升高糖酵解,用2-DG或半乳糖培养基抑制糖酵解可增强HPV阳性细胞对SHetA2的敏感性,联合作用协同且无毒性证据。

要点

  • SHetA2抑制宫颈癌细胞氧化磷酸化,细胞代偿性升高糖酵解。
  • 抑制糖酵解可增强HPV阳性宫颈癌细胞对SHetA2的敏感性,对HPV阴性细胞无此效果。
  • 2-DG与SHetA2在HPV阳性细胞中协同,SiHa异种移植瘤模型验证且无毒性证据。

核心结论

  • 在SHetA2处理的HPV阳性宫颈癌细胞系中,代偿性糖酵解抵消了氧化磷酸化抑制。
  • 用2-DG或其他糖酵解抑制剂阻止代偿性糖酵解,有潜力在无毒性情况下改善SHetA2治疗。

研究设计与样本

  • 在HPV阳性CaSKi和SiHa及HPV阴性C-33 A宫颈癌细胞系中检测SHetA2介导的蛋白质组和代谢效应。
  • 在细胞培养和SiHa异种移植瘤中评估与2-脱氧葡萄糖(2-DG)联合治疗。

主要发现

  • SHetA2抑制氧化磷酸化(OxPhos),并改变参与代谢、蛋白质合成及DNA复制与修复的蛋白水平。
  • 宫颈癌细胞通过升高糖酵解作出反应。
  • 用半乳糖培养基或2-DG抑制糖酵解反应,提高了两种HPV阳性细胞系对SHetA2的敏感性,但未提高HPV阴性宫颈癌细胞系的敏感性。
  • 2-DG与SHetA2在HPV阳性细胞系中呈协同作用,与SHetA2所致ATP降低的增强相关,但与SHetA2诱导的DNA损伤无关。
  • 上述结果在SiHa异种移植瘤模型中得到验证,且无毒性证据。

临床怎么用

  • 原文结论认为,用2-DG或其他糖酵解抑制剂阻止代偿性糖酵解,有潜力在无毒性情况下改善SHetA2治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The high frequency of cervical cancer recurrence after primary therapy necessitates alternative treatments. High-risk human papillomavirus (HR-HPV) causes cervical cancer and it's continued presence supports elevated metabolism, proliferation and survival of cancer cells. The low-to-no toxicity new investigational drug, SHetA2, counteracts high-risk human papillomavirus (HR-HPV) effects on cell proliferation and survival in cervical cancer cells and xenograft tumors by disrupting heat shock protein 70 chaperone protection of oncogenic proteins. Our objective was to study the involvement of metabolism in SHetA2 effects on cervical cancer cells and tumors. METHODS: SHetA2-mediated proteomic and metabolic effects were measured in HR-HPV-positive CaSKi and SiHa and HR-HPV-negative C-33 A cervical cancer cell lines. Combined treatment with 2-deoxyglucose (2-DG) was evaluated in cell culture and SiHa xenografts. RESULTS: SHetA2 inhibited oxidative phosphorylation (OxPhos) and altered levels of proteins involved in metabolism, protein synthesis, and DNA replication and repair. Cervical cancer cells responded by elevating glycolysis. Inhibition of the glycolytic responses using galactose media or 2-DG increased SHetA2 sensitivity of two HR-HPV-positive, but not an HR-HPV-negative cervical cancer cell line. Interaction of 2-DG and SHetA2 was synergistic in HR-HPV positive cell lines in association with augmentation of SHetA2 ATP reduction, but not SHetA2 DNA damage induction. These results were verified in a SiHa xenograft tumor model without evidence of toxicity. CONCLUSIONS: Compensatory glycolysis counteracts OxPhos inhibition in SHetA2-treated HR-HPV-positive cervical cancer cell lines. Prevention of compensatory glycolysis with 2-DG or another glycolysis inhibitor has the potential to improve SHetA2 therapy without toxicity.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rai R, Lightfoot S, Benbrook DM, et al. Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts. Gynecol Oncol. 2023. PMID: 38052108. doi:10.1016/j.ygyno.2023.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。